WilmerHale Advises Nabriva Therapeutics in Term Loan

  • 12.26.2018

WilmerHale advised Nabriva Therapeutics plc (NASDAQ:NBRVF), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, in an up to $75 million term loan with Hercules Capital, Inc. (NYSE:HTGC), $25 million of which was funded on the day of closing.

Brian Johnson and Jamie Class led the WilmerHale team representing Nabriva in this transaction, which also included Ellie Guadiana on credit matters and Scott Lunin and Alex Dzioba on corporate matters. 

Nabriva's announcement regarding the financing can be found at www.nabriva.com.

 
Not sure where to start?

Let our Knowledge Navigator direct you to content specific to where you are on your journey.

Get Started!
Featured
blog-launch-550x370

This blog post explores certain specific terms in term sheets that will create legally binding obligations.

Schall launch feature

Partner Gary Schall shares some practical advice about term sheets: Don’t attempt any transaction without one.

Rss Feed
2.24.2025
Balatro and others re-rated by PEGI after successful appeal, prompting a rule revision 
2.24.2025
Anthropic’s Claude 3.7 Sonnet takes aim at OpenAI and DeepSeek in AI’s next big battle 
2.24.2025
Acid Labs raises $8M to build viral Web3 games on social chat platforms 
Build
Document Generator  
Startup Dictionary  
2.20.2025
Corporate Transparency Act: Judge Clears Way for CTA; Reporting Requirements Back in Effect
2.12.2025
Corporate Transparency Act: It’s Still Paused (For Now)
12.27.2024
Corporate Transparency Act: Preliminary Injunctive Relief Reinstated by Fifth Circuit (For Now)